Highlights Newsletter 2

This newsletter presents you the following key sessions:

1. Podcast with Prof. Dr. Radford about improved overall survival with first-line brentuximab vedotin plus
    chemotherapy in patients with stage III/IV classical Hodgkin lymphoma

2. Sustained clinical benefit with sutimlimab in cold agglutinin disease patients with a history of red blood
    cell transfusion

3. Axicabtagene ciloleucel demonstrates superiority over second-line standard of care in patients
    ≥ 65 years with R/R LBCL

4. Combination of ibrutinib plus venetoclax results in a high rate of MRD-negativity in previously untreated CLL

5. Ibrutinib plus bendamustine-rituximab for treatment naïve mantle-cell lymphoma